Related Experiment Video
Updated: May 12, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
High-output cardiac failure revealing primary plasma cell leukemia
Driss Chaoui1, Bruno Gallet, Philippe Genet
1Service d'Hématologie, Hôpital Victor Dupouy, 69 rue du Lieutenant Colonel Prudhon, 95100 Argenteuil, France.
Insights
High-output cardiac failure in primary plasma cell leukemia can occur without bone disease, linked to arteriovenous shunting. Standard heart failure treatments are ineffective, emphasizing the need for prompt primary plasma cell leukemia therapy.
Area of Science:
- Hematology
- Cardiology
- Oncology
Background:
- High-output cardiac failure (HOCF) is a known complication of multiple myeloma (MM), typically associated with arteriovenous shunting in bone lesions.
- Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma.
Purpose of the Study:
- To describe a case of HOCF in a patient with pPCL without bone disease.
- To review potential mechanisms of HOCF in this context.
- To highlight the implications for patient management.
Main Methods:
- Case report presentation.
- Review of existing literature on MM and pPCL-related cardiac complications.
- Discussion of potential pathophysiological mechanisms.
Main Results:
- A patient with pPCL developed HOCF despite the absence of bone infiltration.
- Arteriovenous shunting was implicated as the cause of HOCF.
- Conventional therapies for cardiac failure were ineffective.
Conclusions:
- HOCF can occur in pPCL even without bone disease, likely due to arteriovenous shunting.
- Standard cardiac failure management strategies are not effective for this specific complication.
- Initiation of pPCL-specific therapy is crucial and should not be postponed.
Abstract:
High-output cardiac failure in multiple myeloma (MM) is related to arteriovenous shunting in bone infiltrate disease. We describe such a complication in a patient with primary plasma cell leukemia (pPCL) without bone disease. We review the mechanisms that could be involved. As previously described, traditional cardiac failure therapy is not effective. pPCL therapy should not be delayed.
Related Concept Videos
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Pathophysiology of Heart Failure